Pharma

Your Article Summary

See Latest Articles

Nabi Biopharmaceuticals Receives Grant Supporting Further NicVAX Development
Nabi Biopharmaceuticals, 09/30/09

Nabi Biopharmaceuticals and the U.S. National Institute on Drug Abuse, part of the National Institutes of Health, announced that NIDA has agreed to extend its support for the continued development of NicVAX(R), Nabi's proprietary vaccine to treat nicotine addiction and prevent smoking relapse. In conjunction with the grant, the Company has decided to proceed with the first pivotal phase III trial, while advancing strategic partnering discussions for the future development and commercialization of NicVAX.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
New England Journal of Medicine, 11/20/09

Intravenous Drug Administration During Out-of-Hospital Cardiac Arrest: A Randomized Trial
JAMA, 11/25/09

Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain
Abbott, 11/16/09

See All of Drug Trials

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

FDA Approves New Test to Aid in the Diagnosis of Rheumatoid Arthritis
Abbott, 10/21/09

Dell Tries to Make an EHR Splash
HealthDataManagement, 11/03/09

Novel agent for treatment of Parkinson's disease - Lu 02-750 - enters Lundbeck's development pipeline
Lundbeck, 11/02/09

See All of Research & Development